OVARIAN CANCER

Disseminated and metastasis 1. Transfer of malignant ovarian tumor growth and metastasis, and other parts of the same direct spread of cancer, and the lymphatic and blood way. But the transfer spread mainly by direct more directly transferred to pots, abdominal organs and organizations, or transfer of Tai omentum, mesenteric, in a number of intraperitoneal nodular mass, a certain degree of mobility; Peritoneal or transferred to the pelvic floor in the vaginal fornix after palpation, palpable in the womb may have rectal Waterloo a papillary protrusions, even penetrating pelvic viscera, a sinus, and the rectum,; a vaginal or urethral cancer tissue from the pus and bleeding. Ovarian cancer found in the lymph node metastasis rate as high as 50%, or even transferred to the left supraclavicular lymph nodes, or perineum, is in the diagnosis and treatment of ovarian cancer, attention. 2. Common vicious invasion on the side of the fixed pelvic advanced malignant ovarian tumors, resulting in partial perivascular infiltration oppression, to the side of lower extremity venous disruption, edema formation. If the intestine of oppression by the vicious invasion, caused obstruction symptoms; Ureteral pressure, often the hydronephrosis. Phase I clinical Asia ovarian cancer metastasis Positions The number of cases Transfer rate (%)

Tags: abdominal, bleeding, blood, cancer, cases, cause, cell, cells, clinical, diagnosis, eat, ert, growth, intraperitoneal, lymph, malignant, mass, metastasis, node, oppression, ovarian, pelvic, rate, symptoms, treatment, tumor, tumors

Most of the malignant ovarian tumors, radiation therapy for various effects are poor. Therefore, in the treatment of malignant ovarian tumor was not first consider radiotherapy. After laparotomy confirmed to be malignant ovarian tumor resection not all, in vitro viable X-ray irradiation. But many of ascites are not OK radiotherapy; The abdominal tumor metastasis to the effect of not limited to those within the pelvic cavity. X-ray irradiation is also used in vitro malignant ovarian tumor before and after surgery. Preoperative radiotherapy for patients with radiation therapy after the word four to six weeks should surgery again night, while radiation caused by adhesions, surgery often caused difficulties. Surgery will be in regular radiation treatment after two weeks before and after the start, such as whole body ill patients should first correct.
(1), abdominal irradiation radiation field including full pots of abdominal viscera, or by Ono divided into two to four vertical irradiation of Ono, tumor dose of 25 Gy ~ / 6 to 8 weeks. General liver, kidney tolerance were 30 Gy and 18 Gy, such as the super-dose, should shielding protection. Whole abdominal irradiation after Ono, the largest general tolerance of 30 Gy / 6 to 7 weeks. This dose is not LD50 of ovarian cancer, while Ono irradiation reaction, difficult patient tolerance. Delcios in 1963, a fully mobile strip abdominal irradiation in the treatment of ovarian cancer. Each abdominal irradiation of 10 cm, radiation field from the upward movement in the entire basin to include abdominal, each irradiation in 12 days. Tumor radiation dose of 26 to 28 Gy. The biological effects of radiation and improve the patient's response to radiotherapy.
(2), pelvic tumor irradiation dose of 40 to 60 Gy, 6 to 8 weeks to complete.
(3), plus whole abdominal pelvic irradiation Ono whole abdominal irradiation may be, or transfer surgery strip irradiation dose with the former. Pelvic organ tolerance, to improve efficacy, and pelvic irradiation dose of 20 to 30 Gy, ovarian cancer is the commonly used method.
(4), abdominal radionuclide therapy for patients early preventive treatment, and only a small residual tumor after treatment. Surgery not cut net of malignant ovarian tumor metastases can be injected with the radioactive colloid 98 or 32 P, or diluted with saline injected into the abdominal cavity to prevent cancer formation of ascites, malignant ovarian cancer has been with ascites, the catheter may produce ascites part, to be injected colloidal gold 98 or 32 P . It should be noted 98 of the radioactive colloid and 32 P for intraperitoneal injection, also caused radioactive hepatitis possible, it should be repeated in application check liver function for timely processing.

Tags: abdominal, body, cancer, cause, days, dose, early, eat, ert, gene, injection, intraperitoneal, irradiation, malignant, metastasis, method, ovarian, patients, pelvic, poor, preventive, radiation, radiotherapy, resection, residual, response, surgery, therapy, time, treatment, tumor, tumors

A large number of pre-clinical data and the right abdominal anatomy, physiology and biology of ovarian cancer have suggested that understanding, abdominal local cytotoxic drug treatment for ovarian cancer is very reasonable. Intraperitoneal chemotherapy Phase I clinical trial confirmed the chemotherapy drugs and intraperitoneal chemotherapy safety of the technology itself, confirmed the intraperitoneal chemotherapy in the pharmacokinetic advantages.

In some multi-center Phase II clinical trials, surgical results confirmed that about 20% to 40% of second-tier category to cisplatin-based chemotherapy in patients with celiac complete remission, the part of the residual cancer patients <0.5 cm before  acceptable to platinum-based chemotherapy effective systemic System .

Tags: abdominal, administration, age, cancer, carboplatin, cause, chemotherapy, cisplatin, clinical, days, drug, drugs, eat, group, incidence, infusion, injection, intraperitoneal, intravenous, ovarian, paclitaxel, pain, patients, rate, reduce, residual, second, study, surgical, survival, taxol, therapy, time, toxicity, treatment, tumor

Patients with malignant ovarian tumor when treatment is late (> Phase II), ovarian cancer is the surgical treatment called tumor or cytoreductive surgery or large resection.
Surgery is to do everything possible to the original tumor resection and can see the pots, peritoneal metastasis, so that each region of residual lesion diameter of less than 2.0 cm to 1.5 cm. Intraoperative from ascites fluid or cells for blood screening. Because ovarian and uterine cancer often, the annex or visco-invasion, peritoneal and keep pots, it is more of "carpet-volume" or "dumplings", from extraperitoneal space elements from the peritoneal wall, bladder and pelvic floor serous peritoneal, along with the uterus and pelvic peritoneum block tumor resection. The pots have peritoneal metastasis tissues or organs should be possible to complete resection or partial resection, resection of the omentum, some intestinal resection, resection of the bladder or ureter shifting values. The removal of the tumor as possible aim is to enhance postoperative radiotherapy and chemotherapy effect. The merger of ovarian cancer ascites, regardless of whether all resection are advised to intraperitoneal indwelling catheter for intraperitoneal injection of anti-cancer drugs. Anti-cancer drugs or radioisotopes for preparation also can be injected directly unresectable tumors.
Surgery can not decide in its benign and malignant ovarian tumor resection specimens should be admitted or contralateral ovarian tissue frozen tablets sent for histopathologic examination. There is no such conditions, generally after the contralateral normal ovarian As can be temporarily retained, pathological specimens were sent checks to clear in nature, and close observation. The previous suspected metastatic ovarian tumor and failed to find its source, should be in operation in detail in the original exploration of abdominal lesions, after further treatment for reference.

Tags: abdominal, annex, anti, benign, blood, cancer, cause, cell, cells, chemotherapy, drug, drugs, eat, examination, exploration, gene, injection, intraperitoneal, malignant, metastasis, metastatic, ovarian, patients, pelvic, radiotherapy, resection, residual, screening, surgery, surgical, therapy, treatment, tumor, tumors, uterine

1). Transfer of malignant ovarian tumor growth and metastasis, and other parts of the same direct spread of cancer, and the lymphatic and blood way. But the transfer spread mainly by direct more directly transferred to pots, abdominal organs and organizations, or transfer of Tai omentum, mesenteric, in a number of intraperitoneal nodular mass, a certain degree of mobility; Peritoneal or transferred to the pelvic floor in the vaginal fornix after palpation, palpable in the womb may have rectal Waterloo a papillary protrusions, even penetrating pelvic viscera, a sinus, and the rectum,; a vaginal or urethral cancer tissue from the pus and bleeding. Ovarian cancer found in the lymph node metastasis rate as high as 50%, or even transferred to the left supraclavicular lymph nodes, or perineum, is in the diagnosis and treatment of ovarian cancer, attention.

Tags: abdominal, bleeding, blood, cancer, cases, cause, clinical, diagnosis, eat, ert, growth, intraperitoneal, lymph, malignant, mass, metastasis, node, oppression, ovarian, pelvic, rate, symptoms, treatment, tumor, tumors

Cytoreductive surgery in the treatment of ovarian cancer Comprehensive Application and prospects

Foreign Medical Obstetrics and Gynecology volumes in 1999 Vol 26 No. 2

Tianjin Medical University General Hospital of Obstetrics and Gynecology (300,052) of the new QU (Summary) if Mi (revision)

Abstract <BR> since the 1980s, complete cytoreductive surgery to cisplatin-based combination chemotherapy for ovarian cancer as a conventional model, cytoreductive surgery is the complete impact of the prognosis of patients with one of the important factors for recurrent ovarian cancer once again cytoreductive surgery still some value , but to improve the survival rate of patients is more important to be effective after chemotherapy treatment as a necessary complement. Early ovarian cancer retroperitoneal lymph node dissection is reasonable and significance of the still controversial.

Tags: abdominal, age, annex, anti, bleeding, blood, cancer, cases, cause, cell, cells, chemotherapy, cisplatin, clinical, diagnosis, drug, drugs, early, eat, ert, exploration, gene, growth, incidence, increased, intraperitoneal, intravenous, life, lymph, malignant, metastasis, metastatic, method, mutation, node, ovarian, p53, patients, pelvic, physical, poor, positive, prognosis, quality, rate, reduce, resection, residual, response, second, staging, study, surgery, surgical, survival, therapy, time, toxicity, treatment, tumor, tumors

Abstract: a group P53 mutations in the genes in patients with advanced ovarian cancer by more cycles of P53 gene therapy and chemotherapy, reducing disease, the survival rate has improved. (The Fourth Annual Gene Therapy & Molecular Biology Conference, Rhodes, Greece)

American University of Iowa Dr. Richard Buller reported they received early treatment to strengthen the 36 patients with advanced ovarian cancer to the adenovirus vector into the peritoneal tumor suppressor gene p53 function of the combination of chemotherapy I / II clinical trials of the preliminary results. The results show that several gene therapy / chemotherapy combination therapy in patients with an average survival of 14.8. Nine people have survived 19.5 months, are still alive. The survival rate is higher than five separate gene therapy on the survival rate is also higher than the average with paclitaxel (Taxol) in the treatment of recurrent ovarian cancer new 15-month survival rate.

Tags: age, cancer, carboplatin, cause, chemotherapy, clinical, early, eat, gene, group, intraperitoneal, mutation, ovarian, p53, paclitaxel, patients, rate, reduce, survival, taxol, therapy, treatment, tumor

[Summary]

Ovarian cancer is a common cancer of female genital mutilation one of the incidence of cervical cancer and after cancer of the uterus, which ranked third. But ovarian cancer death, accounts of the first gynecologic tumors, right pose a serious threat to women's lives. Because ovarian embryonic development, organization anatomy and endocrine function more complicated, it may be suffering from benign tumors or malignant. Because of early ovarian cancer in asymptomatic, and the identification of its type benign and malignant very difficult, ovarian carcinoma laparotomy in ovarian tumor confined to only 30%, most have spread to the uterus, bilateral annex, the omentum and pelvic organs, both in the diagnosis of ovarian cancer and governance the treatment is a major problem indeed. Over the years experts on the pathological form of ovarian cancer, the development of clinical and treatment programs for many of accumulated a lot of experience, so far, statistics on domestic and foreign clinical data, the five-year survival rate of only 25% to 30%.

Tags: abdominal, age, amenorrhea, annex, anti, benign, bleeding, blood, body, cancer, carcinoma, care, cases, cause, cell, cells, chemotherapy, clinical, cyst, cystic, days, diagnosis, dose, drug, drugs, early, eat, ert, estrogen, examination, exploration, gene, grams, growth, gynecological, history, incidence, increased, injection, intraperitoneal, intravenous, irradiation, life, lymph, malignant, mass, metastasis, method, node, oppression, ovarian, ovary, pain, patients, pelvic, poor, prognosis, protein, radiation, radiotherapy, rate, reduce, resection, residual, screening, staging, surface, surgery, surgical, survival, symptoms, syndrome, therapy, time, toxicity, treatment, tumor, tumors, uterine, women

Kikuchi, the Japanese report, have received platinum multidrug chemotherapy for recurrent ovarian cancer Japanese women, a weekly carboplatin and paclitaxel chemotherapy in a meeting, can significantly prolong survival, and patients can be tolerated. (Int J Cancer YORK 2005,15:45)

The case control study included surgery and platinum-based adjuvant chemotherapy complete remission for at least 6 months after the recurrence of ovarian cancer patients. Of the 68 patients, 27 patients received a weekly meeting of Taxol and carboplatin chemotherapy (WTJ) (Group I), carboplatin (AUC area under the curve for 2) plus paclitaxel (80 mg/m2); The remaining 41 patients (Group II) to platinum-based (P ) other chemotherapy, 37 patients with CAP program, a monthly meeting of carboplatin and paclitaxel program four cases.

Tags: cancer, carboplatin, cases, chemotherapy, clinical, drug, drugs, eat, family, gene, group, growth, increased, intraperitoneal, method, ovarian, ovary, p53, paclitaxel, patients, preventive, prognosis, protein, rate, risk, screening, second, study, surgery, survival, syndrome, taxol, therapy, time, treatment, women

Currently, the incidence rates of ovarian cancer accounts for gynecologic malignancy in 23% ~ 27% as the world's five largest high cancer mortality leapt gynecologic tumors in the first place. It can happen to women of any age, but occurred in the before and after menopause, about half occurred after the age of 65.

Tags: administration, age, body, cancer, cause, cell, cells, chemotherapy, clinical, diagnosis, drug, early, eat, ert, examination, gene, gynecological, incidence, intraperitoneal, life, metastasis, method, ovarian, patients, pelvic, quality, radiotherapy, rate, resection, residual, surgery, surgical, survival, symptoms, therapy, time, treatment, tumor, tumors, women